Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.

Hanley KZ, Dureau ZJ, Cohen C, Shin DM, Owonikoko TK, Sica GL.

Cancer Cytopathol. 2018 Apr;126(4):236-242. doi: 10.1002/cncy.21969. Epub 2018 Jan 9.

PMID:
29316326
2.

Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.

Chen G, Magis AT, Xu K, Park D, Yu DS, Owonikoko TK, Sica GL, Satola SW, Ramalingam SS, Curran WJ, Doetsch PW, Deng X.

J Clin Invest. 2018 Jan 2;128(1):500-516. doi: 10.1172/JCI92742. Epub 2017 Dec 11.

3.

Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.

Cassidy RJ, Zhang X, Patel PR, Shelton JW, Escott CE, Sica GL, Rossi MR, Hill CE, Steuer CE, Pillai RN, Ramalingam SS, Owonikoko TK, Behera M, Force SD, Fernandez FG, Curran WJ, Higgins KA.

Cancer. 2017 Oct 1;123(19):3681-3690. doi: 10.1002/cncr.30794. Epub 2017 Jun 13.

PMID:
28608966
4.

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.

Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M, Wu H, McCausland M, Chen Z, Zhang C, Khuri FR, Owonikoko TK, Ahmed R, Ramalingam SS.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. doi: 10.1073/pnas.1705327114. Epub 2017 Apr 26.

5.

Modulation of Bax and mTOR for Cancer Therapeutics.

Li R, Ding C, Zhang J, Xie M, Park D, Ding Y, Chen G, Zhang G, Gilbert-Ross M, Zhou W, Marcus AI, Sun SY, Chen ZG, Sica GL, Ramalingam SS, Magis AT, Fu H, Khuri FR, Curran WJ, Owonikoko TK, Shin DM, Zhou J, Deng X.

Cancer Res. 2017 Jun 1;77(11):3001-3012. doi: 10.1158/0008-5472.CAN-16-2356. Epub 2017 Apr 5.

6.

Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.

Gilbert-Ross M, Konen J, Koo J, Shupe J, Robinson BS, Wiles WG 4th, Huang C, Martin WD, Behera M, Smith GH, Hill CE, Rossi MR, Sica GL, Rupji M, Chen Z, Kowalski J, Kasinski AL, Ramalingam SS, Fu H, Khuri FR, Zhou W, Marcus AI.

JCI Insight. 2017 Mar 9;2(5):e90487. doi: 10.1172/jci.insight.90487.

7.

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R.

Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.

8.

Assays for PD-L1 Expression: Do All Roads Lead to Rome?

Sica GL, Ramalingam SS.

JAMA Oncol. 2017 Aug 1;3(8):1058-1059. doi: 10.1001/jamaoncol.2017.0012. No abstract available.

PMID:
28278316
9.

Construction and Validation of a Multi-Institutional Tissue Microarray of Invasive Ductal Carcinoma From Racially and Ethnically Diverse Populations.

Seijo E, Lima D, Iriabho E, Almeida J, Monico J, Echeverri M, Gutierrez S, Flores I, Lee JH, Fisher K, Grizzle WE, Sica GL, Butler C, Hicks C, Meade CD, Sodeke SO, Moroz K, Coppola D, Munoz-Antonia T.

Cancer Control. 2016 Oct;23(4):383-389.

10.

Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.

Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, Nautiyal V, Chatwal MS, Book WM, Sahu A, Sica GL, Ahmed R, Ramalingam SS.

Cancer Immunol Immunother. 2017 Jan;66(1):45-50. doi: 10.1007/s00262-016-1918-2. Epub 2016 Oct 22.

11.

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.

Owonikoko TK, Zhang G, Kim HS, Stinson RM, Bechara R, Zhang C, Chen Z, Saba NF, Pakkala S, Pillai R, Deng X, Sun SY, Rossi MR, Sica GL, Ramalingam SS, Khuri FR.

J Transl Med. 2016 May 3;14(1):111. doi: 10.1186/s12967-016-0861-5.

12.

Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.

Behera M, Owonikoko TK, Gal AA, Steuer CE, Kim S, Pillai RN, Khuri FR, Ramalingam SS, Sica GL.

Clin Lung Cancer. 2016 Sep;17(5):e57-e64. doi: 10.1016/j.cllc.2016.03.009. Epub 2016 Mar 30. Review.

PMID:
27137345
13.

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.

Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson DH, Delman KA, El-Rayes BF, Wilson MM, Sullivan HC, Morrison AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, Mann KP, Hill CE, Khuri FR, Rossi MR.

J Mol Diagn. 2016 Mar;18(2):299-315. doi: 10.1016/j.jmoldx.2015.11.006. Epub 2016 Jan 20.

14.

A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease.

Bangaru SD, Kozarsky PE, Lee DJ, Sica GL, Owonikoko TK.

World J Oncol. 2015 Aug;6(4):416-420. doi: 10.14740/wjon920w. Epub 2015 Aug 27.

15.

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT, Chen ZG, Shin DM, Ramalingam SS, Khuri FR, Curran WJ, Deng X.

Cancer Cell. 2015 Jun 8;27(6):852-63. doi: 10.1016/j.ccell.2015.04.010. Epub 2015 May 21.

16.

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR.

Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11.

17.

Small-molecule Bax agonists for cancer therapy.

Xin M, Li R, Xie M, Park D, Owonikoko TK, Sica GL, Corsino PE, Zhou J, Ding C, White MA, Magis AT, Ramalingam SS, Curran WJ, Khuri FR, Deng X.

Nat Commun. 2014 Sep 17;5:4935. doi: 10.1038/ncomms5935.

18.

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY.

Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13.

19.

Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.

Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC.

Cancer Prev Res (Phila). 2014 Mar;7(3):351-61. doi: 10.1158/1940-6207.CAPR-13-0254. Epub 2014 Jan 17.

20.

Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer.

You S, Li R, Park D, Xie M, Sica GL, Cao Y, Xiao ZQ, Deng X.

Mol Cancer Ther. 2014 Mar;13(3):606-16. doi: 10.1158/1535-7163.MCT-13-0608. Epub 2013 Dec 20.

21.

Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.

Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri FR, Curran WJ, Shin DM, Deng X.

PLoS One. 2013 Sep 3;8(9):e74670. doi: 10.1371/journal.pone.0074670. eCollection 2013.

22.

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.

Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR, Deng X.

Mol Cancer Ther. 2013 Oct;12(10):2200-12. doi: 10.1158/1535-7163.MCT-13-0095. Epub 2013 Jul 26.

23.

Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.

Park D, Magis AT, Li R, Owonikoko TK, Sica GL, Sun SY, Ramalingam SS, Khuri FR, Curran WJ, Deng X.

Cancer Res. 2013 Sep 1;73(17):5485-96. doi: 10.1158/0008-5472.CAN-12-2272. Epub 2013 Jul 3.

24.
25.

CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC.

Clin Cancer Res. 2013 Mar 15;19(6):1603-11. doi: 10.1158/1078-0432.CCR-12-2995. Epub 2013 Feb 5.

26.

Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotropic hormone-producing pancreatic neuroendocrine cancer.

Chowdry RP, Bhimani C, Delgado MA, Lee DJ, Dayamani P, Sica GL, Owonikoko TK.

Ther Adv Med Oncol. 2012 Nov;4(6):295-300. doi: 10.1177/1758834012456415.

27.

Lung cancer staging: pathology issues.

Sica GL, Gal AA.

Semin Diagn Pathol. 2012 Aug;29(3):116-26. doi: 10.1053/j.semdp.2012.06.001. Review.

PMID:
23062419
28.

Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.

Behera M, Heine JJ, Sica GL, Fowler EE, Tran H, Fu RW, Gal AA, Hermann R, Mayfield W, Khuri FR, Owonikoko TK, Ramalingam SS.

Clin Lung Cancer. 2013 Mar;14(2):128-38. doi: 10.1016/j.cllc.2012.06.001. Epub 2012 Aug 21.

29.

Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.

Liu Y, Sun SY, Owonikoko TK, Sica GL, Curran WJ, Khuri FR, Deng X.

Mol Cancer Ther. 2012 Jan;11(1):45-56. doi: 10.1158/1535-7163.MCT-11-0578. Epub 2011 Nov 4.

30.

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes.

Garg K, Leitao MM Jr, Wynveen CA, Sica GL, Shia J, Shi W, Soslow RA.

Mod Pathol. 2010 Jan;23(1):80-92. doi: 10.1038/modpathol.2009.153. Epub 2009 Oct 23.

31.

Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.

Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG.

Clin Cancer Res. 2009 Apr 1;15(7):2433-41. doi: 10.1158/1078-0432.CCR-08-2179. Epub 2009 Mar 24.

32.

CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.

Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A.

J Thorac Cardiovasc Surg. 2009 Mar;137(3):615-21. doi: 10.1016/j.jtcvs.2008.07.039. Epub 2008 Sep 19.

33.

Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family.

Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L.

J Immunol. 2003 Nov 1;171(9):4650-4.

34.

B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.

Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L.

Immunity. 2003 Jun;18(6):849-61.

36.

B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.

Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L.

Blood. 2001 Mar 15;97(6):1809-16.

37.

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L.

Nat Immunol. 2001 Mar;2(3):269-74.

PMID:
11224528

Supplemental Content

Support Center